Navigation Links
Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis
Date:11/7/2007

golimumab 100 mg, respectively, achieved PASI 75 at week 14, compared with 3 percent of patients receiving placebo (P < 0.001). At week 24, PASI 75 responses improved to 56 percent (golimumab 50 mg) and 66 percent (golimumab 100 mg), compared with 1 percent of placebo patients (P < 0.001). In additional analyses, patients receiving golimumab 50 mg and golimumab 100 also experienced improvements in nail psoriasis as measured by NAPSI and these improvements were sustained over time.

"These Phase 3 data show that once monthly subcutaneous administrations of golimumab 50 mg and golimumab 100 mg significantly improved articular and psoriatic manifestations in patients with psoriatic arthritis," said Jerome A. Boscia, MD, senior vice president, Clinical Research and Development, Centocor, Inc. "We are encouraged by these results and believe golimumab holds great promise as a new anti-TNF-alpha therapy for physicians and patients in need of additional therapeutic options."

Disease Activity and Physical Function Improvements

The majority of golimumab-treated patients in the study were classified as good or moderate responders as measured by the Disease Activity Score 28 (DAS28), which measures tender and swollen joints and overall disease activity including measurement of serum C-reactive protein (CRP) levels. After 14 weeks of treatment, 66 percent of patients receiving golimumab 50 mg were DAS28 responders, as were 67 percent of patients receiving the 100 mg dose, compared with 24 percent of patients receiving placebo (P < 0.001). At week 24, 64 percent and 78 percent of patients receiving golimumab 50 mg and 100 mg, respectively, were DAS28 responders, compared with 24 percent of patients receiving placebo (P < 0.001).

Patients receiving golimumab in the study also experienced significant improvements in physical function, as measured by the Health Assessment Questionnaire (HAQ). At week 14, patients receiving golimumab 50 mg experienced a mean i
'/>"/>

SOURCE Centocor Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... YORK , Aug. 20, 2014 ... is available in its catalogue: Global ... http://www.reportlinker.com/p01375204/Global-Coatings-for-Medical-Devices-Industry.html This report ... Devices in US$ Million by the following Product ... Nanotechnology Coatings. The report provides separate comprehensive analytics ...
(Date:8/20/2014)... PHOENIX , Aug. 20, 2014 ... cutting-edge next-generation sequencing and proteomic diagnostics and biomarker ... a collaboration with TESARO, Inc.  Paradigm will use ... samples from clinical trials to better predict which ... TSR-011.  This may lead to more successful clinical trial ...
(Date:8/20/2014)... ApolloDx™ today announced it will unveil and ... event at the company,s office in Salt ... The event, which will start at 10:00 a.m., will ... .    "We believe our mobile diagnostic ... , Co-Founder and Managing Partner of ApolloDx. In addition ...
Breaking Medicine Technology:Global Coatings for Medical Devices Industry 2Global Coatings for Medical Devices Industry 3Global Coatings for Medical Devices Industry 4Global Coatings for Medical Devices Industry 5Global Coatings for Medical Devices Industry 6Global Coatings for Medical Devices Industry 7Global Coatings for Medical Devices Industry 8Global Coatings for Medical Devices Industry 9Global Coatings for Medical Devices Industry 10Global Coatings for Medical Devices Industry 11Global Coatings for Medical Devices Industry 12Global Coatings for Medical Devices Industry 13Global Coatings for Medical Devices Industry 14Global Coatings for Medical Devices Industry 15Global Coatings for Medical Devices Industry 16Global Coatings for Medical Devices Industry 17Global Coatings for Medical Devices Industry 18Global Coatings for Medical Devices Industry 19Global Coatings for Medical Devices Industry 20Global Coatings for Medical Devices Industry 21Paradigm Announces Molecular Profiling Collaboration with TESARO, Inc. 2
... WuXi PharmaTech (Cayman) Inc. (NYSE: WX ), ... company with operations in China and the United States, ... the third quarter of 2011 after the New York ... will be Friday morning, November 11, 2011 Shanghai time). ...
... 2011 Philips Respironics, a unit of Royal Philips ... treating and managing the full spectrum of sleep and ... kind at Medtrade 2011. The largest national educational and ... (HME) industry kicks off this week at Georgia World ...
Cached Medicine Technology:WuXi PharmaTech Schedules Third-Quarter 2011 Earnings Release 2Philips Respironics Unveils "Pathway to Better Outcomes" for Home Health Care 2Philips Respironics Unveils "Pathway to Better Outcomes" for Home Health Care 3Philips Respironics Unveils "Pathway to Better Outcomes" for Home Health Care 4
(Date:8/20/2014)... iFitDress.com, the well-known wedding dress manufacturer and retailer, ... evening gowns . All items in the fresh collection ... $100. , iFitDress.com is among the hardest working ... best to help clients worldwide to keep pace with ... and professional. According to its development manager, all its ...
(Date:8/20/2014)... August 20, 2014 The ... (IBCCES) , an organization recognizing professionals dedicated to ... has announced that with a certificate in ... people on the Autism Spectrum have a way ... quality care. This, in turn, say IBCCES representatives, ...
(Date:8/20/2014)... 20, 2014 Ticket Down is a ... in NYC. In just a week, the U.S. Open Tennis ... Center. The event was originally founded in 1881 and features grass ... was forced to withdrawal from the event because of a wrist ... and will return to New York City with hopes of winning ...
(Date:8/20/2014)... Line: A study in Australia examined patient and ... (a marker of tumor cell growth) in an ... cancer in patients. , Author: ... Victoria, Australia, and colleagues. , Background: The ... cell division) has been connected with prognosis and ...
(Date:8/20/2014)... deploy Ebola vaccines is now, Free content, The ... to a commentary being published early online today in ... authors from Yale School of Public Health write that ... current Ebola outbreak represent a public health crisis that ... Ebola vaccines have been developed in the last decade, ...
Breaking Medicine News(10 mins):Health News:iFitDress.com Releases a New Range of Cheap Evening Gowns 2Health News:National Autism Certificate Credentialing Board IBCCES Increases Job Placement Opportunities for Those Dedicated to Working Within the Autism Spectrum 2Health News:National Autism Certificate Credentialing Board IBCCES Increases Job Placement Opportunities for Those Dedicated to Working Within the Autism Spectrum 3Health News:2014 U.S. Open Tennis Tickets: Ticket Down Slashes Ticket Prices on All US Open Tennis Championship Sessions in New York at Arthur Ashe Stadium 2Health News:2014 U.S. Open Tennis Tickets: Ticket Down Slashes Ticket Prices on All US Open Tennis Championship Sessions in New York at Arthur Ashe Stadium 3Health News:2014 U.S. Open Tennis Tickets: Ticket Down Slashes Ticket Prices on All US Open Tennis Championship Sessions in New York at Arthur Ashe Stadium 4Health News:2014 U.S. Open Tennis Tickets: Ticket Down Slashes Ticket Prices on All US Open Tennis Championship Sessions in New York at Arthur Ashe Stadium 5Health News:Patient, tumor characteristics for high-mitotic rate melanoma 2Health News:News from Annals of Internal Medicine 2
... Taking serious note of doctors using advertisements to lure ... Monday asked the state's medical council to take steps ... education and research minister Tikshan Sood said here that ... but also a violation of the Medical Council Act. ...
... say that they have developed a faster, less expensive ... stretches of DNA. The development of the new technique ... mutant genes, but also from mutations of other DNA ... occur as a consequence of deleting non-gene DNA sequences, ...
... that playing with candy cigarettes may favorably set the ... . , The study, reported in the ... nationally representative sample of 25,887 US adults, the percentages ... current and former smokers vs. 22% in never smokers, ...
... discovery by Fox Chase Cancer Center researchers helps explain ... viral diseases. The research shows lymph nodes are not ... also are the sites where a major fight against ... ,After becoming sick from many viruses, the body becomes ...
... dogs are at risk of suffering broken bones, torn ... owner and pet, there are veterinarians who can ... feet. James Roush, an orthopedic surgeon at the Veterinary ... such veterinarian. ,Roush frequently performs orthopedic surgeries ...
... a team of Emory University scientists have found a ... mutations recently identified in Parkinson disease development. These new findings ... provide a target for drug therapies to treat the disease. ... central nervous system resulting from the loss of neurons in ...
Cached Medicine News:Health News:Boffins Develop New Technique to Hunt Illness-causing Mutants in Non-gene DNA 2Health News:The Danger in Candy Cigarettes 2Health News:Memory T Cells Protect the Body from Viruses 2Health News:Some Common Human Injuries Also Common in Dogs 2Health News:Some Common Human Injuries Also Common in Dogs 3Health News:Parkinsons Disease Protein Pathway Identified 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: